Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie.

Kaechele V, Moehler M, Lutz MP, von Wichert G, Eisele M, Klaus J, Galle PR, Adler G, Seufferlein T.

Cancer Chemother Pharmacol. 2010 May;66(1):191-5. doi: 10.1007/s00280-010-1312-2. Epub 2010 Mar 31.

PMID:
20354701
2.

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.

Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie..

J Clin Oncol. 2008 Mar 20;26(9):1435-42. doi: 10.1200/JCO.2007.13.9378.

PMID:
18349393
3.

Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer.

Polee MB, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Verweij J, Stoter G, van der Gaast A.

Br J Cancer. 2002 Mar 4;86(5):669-73.

4.

Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.

Geh JI, Glynne-Jones R, Kwok QS, Banerji U, Livingstone JI, Townsend ER, Harrison RA, Mitchell IC.

Clin Oncol (R Coll Radiol). 2000;12(3):182-7.

PMID:
10942336
5.

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.

Jones RJ, Hawkins RE, Eatock MM, Ferry DR, Eskens FA, Wilke H, Evans TR.

Cancer Chemother Pharmacol. 2008 Mar;61(3):435-41. Epub 2007 Apr 18.

PMID:
17440725
6.

A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.

Scott LC, Yao JC, Benson AB 3rd, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR.

Cancer Chemother Pharmacol. 2009 Jan;63(2):363-70. doi: 10.1007/s00280-008-0746-2. Epub 2008 Apr 9.

PMID:
18398613
7.

Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.

Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C.

Anticancer Drugs. 2002 Jun;13(5):497-503.

PMID:
12045461
8.

A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer.

Cao W, Xu C, Lou G, Jiang J, Zhao S, Geng M, Xi W, Li H, Jin Y.

Jpn J Clin Oncol. 2009 Sep;39(9):582-7. doi: 10.1093/jjco/hyp058. Epub 2009 Jun 9.

PMID:
19509000
9.

Multi-center phase II trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer.

Sun Q, Liu C, Zhong H, Zhong B, Xu H, Shen W, Wang D.

Jpn J Clin Oncol. 2009 Apr;39(4):237-43. doi: 10.1093/jjco/hyp008. Epub 2009 Mar 4.

PMID:
19264768
10.

A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.

Eatock MM, Anthony DA, El-Abassi M, Wilson P, Paul J, Smith M, Soukop M, Evans TR.

Br J Cancer. 2000 Jun;82(12):1925-31.

11.

Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction.

Sharma A, Raina V, Lokeshwar N, Deo SV, Shukla NK, Mohanti BK.

Indian J Cancer. 2006 Jan-Mar;43(1):16-9.

12.

Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.

Polee MB, Verweij J, Siersema PD, Tilanus HW, Splinter TA, Stoter G, Van der Gaast A.

Eur J Cancer. 2002 Jul;38(11):1495-500.

PMID:
12110496
13.

Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.

Lim JY, Cho JY, Oh KJ, Choi SH, Lee SI, Jeung HC.

Chemotherapy. 2009;55(4):200-6. doi: 10.1159/000219434. Epub 2009 May 19.

PMID:
19451710
14.

Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.

Safran H, Akerman P, Cioffi W, Gaissert H, Joseph P, King T, Hesketh PJ, Wanebo H.

Semin Radiat Oncol. 1999 Apr;9(2 Suppl 1):53-7.

PMID:
10210540
15.

A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.

Nakajo A, Hokita S, Ishigami S, Miyazono F, Etoh T, Hamanoue M, Maenohara S, Iwashita T, Komatsu H, Satoh K, Aridome K, Morita S, Natsugoe S, Takiuchi H, Nakano S, Maehara Y, Sakamoto J, Aikou T; Kyushu Taxol TS-1 Study Group..

Cancer Chemother Pharmacol. 2008 Nov;62(6):1103-9. doi: 10.1007/s00280-008-0693-y. Epub 2008 Mar 4.

PMID:
18317763
16.

Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.

Jung JY, Kwon JH, Kim JH, Song HH, Kim I, Lee KS, Kim HJ, Zang DY, Ahn JS, Lee JA, Park YI.

Oncol Rep. 2009 Feb;21(2):523-9.

PMID:
19148531
17.

Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer.

Laohavinij S, Maoleekoonpairoj S, Cheirsilpa A, Maneechavakajorn J, Sirachainant E, Arpornvivat W, Jaisathaporn K, Ratanatharathorn V.

Lung Cancer. 1999 Dec;26(3):175-85.

PMID:
10598928
18.

[Oxaliplatin-based regimen for the treatment of advanced or metastatic gastric/esophagogastric junction cancer].

Li J, Lu M, Shen L, Zhang XD, Li Y.

Zhonghua Zhong Liu Za Zhi. 2009 Dec;31(12):933-6. Chinese.

PMID:
20193337
19.

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.

Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, Seipelt G, Rost A, Orth J, Knuth A, Jaeger E.

J Clin Oncol. 2004 Feb 15;22(4):658-63.

PMID:
14966088
20.

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.

Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A, Jäger E.

Ann Oncol. 2008 Nov;19(11):1882-7. doi: 10.1093/annonc/mdn403. Epub 2008 Jul 31.

PMID:
18669868

Supplemental Content

Support Center